New Study Finds TGFB2 as Key Survival Marker in Young Pancreatic Cancer Patients

SAPU Bioscience's Comprehensive Data Analysis

Highlights

Sapu Biosciences, LLC, a fully owned subsidiary of GMP Biotechnology Limited (GMP Bio), in partnership with Oncotelic Therapeutics, Inc., a biopharmaceutical company unlocking new stages of small molecule and RNA-targeted therapeutics for rare diseases and cancer, showcased the publishing of new translation research evaluation of TGFB2 expression and represent methylation as a capable prognostic markers in PDAC pancreatic ductal adenocarcinoma. In the article ‘TGFB2 expression and methylation predict overall survival in pancreatic ductal adenocarcinoma patients’, printed in the International Journal of Molecular Sciences (IJMS), the work included an alliance with Sapu.

The clinical data from the OT-101 P001 PDAC study have emphasized that targeting TGFB2 merits evaluation in younger patients, with the treatment of a subset differentiated by low IL-6 median OS taking 12.7 months. The new findings and the analysis of the new potential performing better as an option is a scientific heritage of the healthcare sector since its development and improvement in clinical studies and research & development. These findings will surely bring change in the medication for the PDAC. Also, the article is an awareness campaign for healthcare professionals and hospitals.

Views and Statements

Co-author of the study and director of Eisenberg Center for Translational Therapeutics and co-director of gastro-enterology oncology program at Karmanos Cancer Institute, MD, Professor Wasif Saif said, “these new findings have helped clinicians to pave practical way to stratified design and patients more properly, and also helps to focus on age trial. the finding is an emergency to call up on the lethal disease.  OT-101, TGFB2 aimed approach is capable of testing in randomized clinical trials. The analysis encountered that the high TGFB2 expression is aligned with decreased overall survival (OS) in patients registered under 65 (TGFB2 high median vs. low median OS: 17.9 vs. 66.9 months) but not the same in older cohorts.”

Further, “The most accelerated TGFB2 methylation witnessed improvement in survival in younger patients (high methylation vs low methylation median OS:66.9 vs 17.9 months). Our clinical data from a pancreatic ductal adenocarcinoma trial in OT-101, which is an antisense oligonucleotide targeting TGFB2, has supported these findings by highlighting that the young patients receiving OT-101 experienced improvement in OS in comparison to untreated controls. TGFB2 indicates the younger subset of pancreatic cancer patients most probably witness poor survival, and the clinicians are facing more challenges due to the underlying patient population in the last few years.”